New Zealand markets closed
  • NZX 50

    11,730.52
    -29.49 (-0.25%)
     
  • NZD/USD

    0.6454
    +0.0023 (+0.36%)
     
  • NZD/EUR

    0.6286
    +0.0060 (+0.97%)
     
  • ALL ORDS

    7,288.80
    -36.60 (-0.50%)
     
  • ASX 200

    7,032.50
    -38.50 (-0.54%)
     
  • OIL

    91.58
    -2.76 (-2.93%)
     
  • GOLD

    1,817.20
    +10.00 (+0.55%)
     
  • NASDAQ

    13,545.32
    +253.34 (+1.91%)
     
  • FTSE

    7,500.89
    +34.98 (+0.47%)
     
  • Dow Jones

    33,705.39
    +368.72 (+1.11%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • Hang Seng

    20,175.62
    +93.19 (+0.46%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • NZD/JPY

    86.1080
    +0.6210 (+0.73%)
     

Chief Financial Officer Narayan Prabhu Just Bought A Handful Of Shares In Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

·3-min read

Whilst it may not be a huge deal, we thought it was good to see that the Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Chief Financial Officer, Narayan Prabhu, recently bought US$61k worth of stock, for US$1.21 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

View our latest analysis for Reviva Pharmaceuticals Holdings

The Last 12 Months Of Insider Transactions At Reviva Pharmaceuticals Holdings

Notably, that recent purchase by Narayan Prabhu is the biggest insider purchase of Reviva Pharmaceuticals Holdings shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.20). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Narayan Prabhu was the only individual insider to buy during the last year.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Reviva Pharmaceuticals Holdings

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 26% of Reviva Pharmaceuticals Holdings shares, worth about US$4.8m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Reviva Pharmaceuticals Holdings Insiders?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Reviva Pharmaceuticals Holdings shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Reviva Pharmaceuticals Holdings. To help with this, we've discovered 4 warning signs (1 makes us a bit uncomfortable!) that you ought to be aware of before buying any shares in Reviva Pharmaceuticals Holdings.

Of course Reviva Pharmaceuticals Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting